Cargando…
Bringing cell therapy to tumors: considerations for optimal CAR binder design
Chimeric antigen receptor (CAR)-T cells have revolutionized the immunotherapy of B-cell malignancies and are poised to expand the range of their impact across a broad range of oncology and non-oncology indications. Critical to the success of a given CAR is the choice of binding domain, as this is th...
Autor principal: | Smith, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576856/ https://www.ncbi.nlm.nih.gov/pubmed/37846297 http://dx.doi.org/10.1093/abt/tbad019 |
Ejemplares similares
-
The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018) -
Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy
por: Marofi, Faroogh, et al.
Publicado: (2021) -
Optimizing Therapies in Heart Failure: The Role of Potassium Binders
por: Scicchitano, Pietro, et al.
Publicado: (2022) -
Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy
por: Liu, Zaoqu, et al.
Publicado: (2022) -
CAR T-Cell Therapy in Children with Solid Tumors
por: Kulczycka, Marika, et al.
Publicado: (2023)